TSCAN THERAPEUTICS, INC. (TCRX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $632.90M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-563.89M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $630.44M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-533.53M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $627.98M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-504.86M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in Capital, Common StockUSD $625.90M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.00K; Retained Earnings (Accumulated Deficit)USD $-481.88M.
TSCAN THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Common Stock, Value, Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $632.90M | (m) | $-563.89M | $69.02M | (m) | 3 month · $2.36M 6 month · $4.82M | (m) | (m) |
| 2026-03-31 | (m) | $630.44M | (m) | $-533.53M | $96.92M | (m) | 3 month · $2.46M | (m) | (m) |
| 2025-12-31 | (m) | $627.98M | (m) | $-504.86M | $123.12M | (m) | 12 month · $11.71M | (m) | (m) |
| 2025-09-30 | $0.00 | $625.90M | $2.00K | $-481.88M | $144.02M | (m) | 3 month · $3.01M 9 month · $9.70M | (m) | (m) |
| 2025-06-30 | $0.00 | $622.89M | $-4.00K | $-446.18M | $176.71M | (m) | 3 month · $3.27M 6 month · $6.69M | (m) | (m) |
| 2025-03-31 | $0.00 | $619.42M | $-4.00K | $-409.22M | $210.20M | (m) | 3 month · $3.41M | (m) | (m) |
| 2024-12-31 | $0.00 | $616.01M | $51.00K | $-375.10M | $240.97M | 12 month · $14.75M | 12 month · $9.55M | 12 month · $158.07M | (m) |
| 2024-09-30 | $0.00 | $568.37M | (m) | $-339.29M | $229.09M | (m) | 3 month · $2.52M 9 month · $6.83M | 9 month · $128.27M | (m) |
| 2024-06-30 | $0.00 | $564.62M | (m) | $-309.40M | $255.22M | (m) | 3 month · $2.33M 6 month · $4.31M | 3 month · $128.27M 6 month · $128.27M | (m) |
| 2024-03-31 | $0.00 | $400.70M | (m) | $-277.74M | $122.97M | (m) | 3 month · $1.98M | (m) | (m) |
| 2023-12-31 | $0.00 | $398.46M | (m) | $-247.60M | $150.87M | (m) | 12 month · $5.21M | 12 month · $92.32M | (m) |
| 2023-09-30 | (m) | $396.94M | (m) | $-227.98M | $168.96M | (m) | 3 month · $1.34M 9 month · $3.71M | 9 month · $92.32M | (m) |
| 2023-06-30 | (m) | $395.59M | (m) | $-204.99M | $190.61M | (m) | 3 month · $1.22M 6 month · $2.37M | 3 month · $92.32M 6 month · $92.32M | (m) |
| 2023-03-31 | (m) | $258.96M | (m) | $-180.94M | $78.02M | (m) | 3 month · $1.15M | (m) | (m) |
| 2022-12-31 | (m) | $257.81M | (m) | $-158.38M | $99.43M | (m) | 12 month · $4.55M | (m) | (m) |
| 2022-09-30 | (m) | $256.31M | (m) | $-139.66M | $116.66M | (m) | 3 month · $1.25M 9 month · $3.25M | (m) | (m) |
| 2022-06-30 | (m) | $255.06M | (m) | $-123.41M | $131.65M | (m) | 3 month · $1.02M 6 month · $2.01M | (m) | (m) |
| 2022-03-31 | (m) | $254.00M | (m) | $-108.31M | $145.69M | (m) | 3 month · $984.00K | (m) | (m) |
| 2021-12-31 | (m) | $252.93M | (m) | $-92.16M | $160.78M | (m) | 12 month · $2.52M | (m) | (m) |
| 2021-09-30 | (m) | $252.03M | (m) | $-77.96M | $174.07M | (m) | 3 month · $885.00K 9 month · $1.73M | (m) | (m) |
| 2021-06-30 | (m) | $2.09M | (m) | $-62.12M | $-60.03M | (m) | 3 month · $503.00K 6 month · $847.00K | (m) | $1.00K |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-49.92M | (m) | 3 month · $344.00K | (m) | (m) |
| 2020-12-31 | (m) | $1.07M | (m) | $-43.53M | $-42.46M | (m) | 12 month · $515.00K | (m) | $1.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-34.84M | (m) | 3 month · $128.00K 9 month · $365.00K | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-27.80M | (m) | 3 month · $126.00K 6 month · $237.00K | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-22.34M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-17.14M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |